Australia markets close in 12 minutes
  • ALL ORDS

    6,684.30
    +16.80 (+0.25%)
     
  • ASX 200

    6,485.20
    +15.80 (+0.24%)
     
  • AUD/USD

    0.6503
    +0.0045 (+0.69%)
     
  • OIL

    77.61
    +0.90 (+1.17%)
     
  • GOLD

    1,641.40
    +8.00 (+0.49%)
     
  • BTC-AUD

    30,961.72
    +1,843.53 (+6.33%)
     
  • CMC Crypto 200

    460.12
    +27.02 (+6.24%)
     
  • AUD/EUR

    0.6735
    +0.0023 (+0.34%)
     
  • AUD/NZD

    1.1398
    -0.0049 (-0.43%)
     
  • NZX 50

    11,214.49
    -220.33 (-1.93%)
     
  • NASDAQ

    11,254.11
    -57.13 (-0.51%)
     
  • FTSE

    7,020.95
    +2.35 (+0.03%)
     
  • Dow Jones

    29,260.81
    -329.60 (-1.11%)
     
  • DAX

    12,227.92
    -56.27 (-0.46%)
     
  • Hang Seng

    17,725.82
    -129.32 (-0.72%)
     
  • NIKKEI 225

    26,531.66
    +100.11 (+0.38%)
     

Herborium®’ Group Half Year Update

·3-min read

Debt Elimination, Maintaining Sales and New Initiatives In Focus

Houston, July 21, 2022 (GLOBE NEWSWIRE) -- Houston, Texas, 07/21/2022. Herborium Group, Inc.  (OTC Pink: HBRM),  a Botanical Therapeutics Company and provider of unique, all botanical medicinal, beauty and wellness  products with a clinically validated records of efficacy and safety, announced today the following accomplishments for the first half of 2022. The Company also shares with Investors the plan for the remaining months of the year.

  • According to prior announced plans, the Company eliminated $200,000 in corporate debts without dilutive financing or issuing additional corporate shares.  The Company will continue its efforts to reduce debt without dilution, possibly retire shares and to increase shareholders value.  

  • The Company stayed current and maintained the Highest Tier of Reporting on OTC. Almost 2000 companies were  eliminated from OTC  for lack of regulatory compliance and reporting.

  • Despite inflationary pressure and other disadvantageous economic factors the Company maintains strong sales during the entire six month period.  Herborium improved its margins from 61% of 64% and developed some new business alliances. These alliances are expected to be monetized during the next 6-12 months.

  • During the past six months, the company accelerated its transformation from an Acne Treatment Company to  become an interactive, AI based platform for integrated product, content and expertise in the area or skincare: The introduction of the first stage of SKIN-NATURA® is expected in the 4th Quarter of 2022.   With a strong global trend towards using natural products, with a 21% growth in on online beauty business since 2018 and over 75% of women and over 55% of men purchasing their selfcare products online, Herborium’s expansion of its platform opens new growth opportunities for the Company.

  • Due to Herborium’s unique expertise, the new platform will provide all needed deliverables for consumers and professionals seeking natural alternatives to serious self-care concerns (initially skincare problems) unanswered by traditional providers.

  • This innovative technology platform will allow the Company to establish a Consortium of preselected natural products and know-how partners that together provide one of a kind, comprehensive, easy to use and friendly to access one stop shopping for personalized selfcare products. In addition, regimens, treatment options, counseling, advisement, medical and nutritional assistance and a curated consumer forum in the natural wellness and beauty space will be provided.

  • This new business model will allow Herborium to realize multiple revenue streams, significantly expand its market reach, increase consumer satisfaction and loyalty as well as create additional shareholders value through revenue growth and increased brand recognition.  This initiative will also provide potential for further partnerships and acquisitions.

About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics company that develops, license and markets proprietary, botanical based medicinal and wellness products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products to establish and maintain a differential advantage. Herborium has secured a pipeline of botanical ingredients based products in the areas of dermatological needs, wellness and energy, women’s health and selected sexual disorders and has built the versatile, technologically advanced, interactive content platform to support consumer needs.  Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. For more information, please visit www.herborium.com, www.acnease.comwww.acnease.fr and www.acneasesp.com

Safe Harbor Statement: This release contains forward-looking statements with respect to the results of operations and business of Herborium Group, Inc., which involves risks and uncertainties. The Company's actual future results could materially differ from those discussed.  The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.

CONTACT: Herborium Group, Inc. CustomerService@Herborium.com ; Investorrelations@Herborium.com